Sophia (Sujin) Kim 1/5/26 Sophia (Sujin) Kim 1/5/26

Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs

SungJoo Lee 12/18/25 SungJoo Lee 12/18/25

Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases

Sophia (Sujin) Kim 12/8/25 Sophia (Sujin) Kim 12/8/25

Orum Therapeutics Presents Preclinical Data at ASH 2025 Demonstrating Potent and Selective Antitumor Activity of ORM-1153, a CD123-Targeting Degrader Antibody Conjugate for Acute Myeloid Leukemia

Sophia (Sujin) Kim 11/3/25 Sophia (Sujin) Kim 11/3/25

Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting

Sophia (Sujin) Kim 10/15/25 Sophia (Sujin) Kim 10/15/25

Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum’s Degrader–Antibody Conjugate Payload Platforms and Expand TPD²® Therapeutic Applications